In this online, self-learning activity:
In the U.S., there are over 22,000 new cases of ovarian cancer and close to 14,000 related deaths per year. ~ 90% of malignant ovarian tumors are epithelial carcinomas (serous, endometrioid, mucinous, clear cell, transitional cell, and squamous) while the remainder are non-epithelial (germ cell, sex cord/stromal tumors). Risk factors for ovarian cancer includes: early menarche and late menopause, nulliparity, family history of breast cancer or ovarian cancer, and BRCA1 or -2 mutations; whereas factors associated with a protective effective include: oral contraceptives, breastfeeding, and tubal ligation, among others.
Described as a neoplastic “silent killer” for its nonspecific symptomology and the likelihood that it will not present until disease has progressed, the 5-year survival rate in ovarian cancer drops precipitously from better than 90% when the disease is localized to between 10% and 30% once it has advanced. The initial workup of the pelvic mass includes abdominal imaging with assessment of other symptoms including bloating, early satiety and/or loss of appetite, pelvic or abdominal pain, increased urinary urgency and frequency, irritable bowel syndrome, unexplained weight loss/fatigue/changes in bowel habits, and ascites as clinically warranted.
HCPs specializing in: medical oncologists and oncology surgeons; physician assistants, nurse practitioners, nurses, and pharmacists who practice in oncology; and other clinicians who commonly encounter patients with ovarian cancer or those who might benefit from screening.
Commercial Support Disclosure: This program is supported by an educational grant from Merck.
This activity is free of charge.
Release Date: April 16, 2020 -- Expiration Date: April 16, 2022
Faculty: June Hou, MD
Faculty introduction, disclosures |
Introduction content: cursory refresher and review
|
Treatment strategies in ovarian cancer How has the treatment landscape changed in the last decade, and where is it going?
|
Summary, conclusions, and best practice recap |
By the end of the session the participant will be able to:
ACCME Activity #0
This activity has been planned and implemented in accordance with the accreditation standards and policies of the Accreditation Council for Continuing Medical Education through ScientiaCME. ScientiaCME is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation: ScientiaCME designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ toward the AMA Physician's Recognition Award. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Physicians: Please note: not all activities on this site provide MOC credit. If this activity does not specify that it provides MOC credit in the "Accreditation" section on this page, then it does NOT provide MOC credit.
Pharmacists
ScientiaCME is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hours (0.1 CEUs) of continuing pharmacy education credit. Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit. ACPE # 0574-0000-20-015-H01-P. ACPE Accreditation effective 4/25/2020, expires 4/25/2022. This is a Application (A)-type activity.
Pharmacists: You must enter your NABP # and birth date correctly so that proof of participation can be posted to your NABP CPE profile. It is the learner's responsibility to provide this information completely and accurately at the completion of the activity. Without providing it, the learner will NOT receive CPE credit for this activity.
Nurse Practitioners (NPs): The American Academy of Nurse Practitioners accepts AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME. ScientiaCME will provide NPs who successfully complete each activity with a certificate of participation indicating that the activity was designated for AMA PRA Category 1 Credit(s)™.
Physician Assistants: The American Academy of Physician Assistants accepts AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.
As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.
Faculty Disclosure: June Y. Hou, MD, Assistant Professor of Gynocologic Oncology, Columbia University, Ervings Medical Center, New York, has received financial compensation as a consultant for Foundation Medicine, Inc., Massive Bio, Inc., and Immunogen Inc.
Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.
Commercial Support Disclosure: This program is supported by an educational grant from Merck.
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.
Recurrent and metastatic endometrial cancer: Therapeutic updates and optimizing treatment